Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer
Phase II Pilot Study of Trastuzumab Biosimilar (Herzuma®) plus Gedatolisib in Patients with HER-2 Positive Metastatic Breast Cancer Who Progressed after 2 or more HER-2 directed Chemotherapy
HER2-positive Breast Cancer|Metastatic Breast Cancer
DRUG: Trastuzumab biosimilars(Herzuma), Gedatolisib
Objective response rate, the percentage of patients experiencing confirmed complete response (CR) and partial response (PR) assessed by RECIST criteria v.1.1, within maximum 3 years
Progression free survival, the time from study entry until the first observation of disease progression according to the above schedule or death due to any cause, within maximum 3 years|Overall survival, the time from study entry until death, within maximum 3 years
All the patients will be included in the final analysis, with a total of 15 patients to be enrolled.

Treatment will occur until disease progression, unacceptable toxicity or patient withdrawal.

Tumor measurement and evaluation are going to be performed at every 6 weeks for the first 3 months, then at every 9 weeks till progression, and then follow-up evaluation at every 12 weeks thereafter end of study.